Sugammadex To IMprove Bowel Function

PHASE4CompletedINTERVENTIONAL
Enrollment

120

Participants

Timeline

Start Date

March 16, 2021

Primary Completion Date

June 14, 2023

Study Completion Date

August 13, 2023

Conditions
Bowel DysfunctionPostoperative ComplicationsNeuromuscular Blockade
Interventions
DRUG

Sugammadex

At the end of the surgical procedure at a depth of neuromuscular blockade after the reappearance of T2 on the train-of-four, Sugammadex will be dosed once at 2 mg/kg actual body weight through an intravenous line with brisk flow

DRUG

Neostigmine

At the end of surgical procedure at a depth of neuromuscular blockade after the reappearance of T2 on the train-of-four, Neostigmine will be dosed once at 0.07 mg/kg actual body weight to a maximum of 5 mg through an intravenous line with brisk flow. Glycopyrrolate will be coadministered with Neostigmine at a dose of 0.2 mg of Glycopyrrolate per 1.0 mg of Neostigmine administered

Trial Locations (1)

97239

Oregon Health & Science University, Portland

All Listed Sponsors
collaborator

Merck Sharp & Dohme LLC

INDUSTRY

lead

Oregon Health and Science University

OTHER

NCT04546672 - Sugammadex To IMprove Bowel Function | Biotech Hunter | Biotech Hunter